Table 1.
SARP Cross-sectional Cohort Microarray mRNA (n = 155) | Nonsmoking Control Subjects (n = 27) | Nonsmoking Asthma* (n = 128) | Nonsevere Asthma† (n = 78) | Severe Asthma† (n = 50) | P Value‡ (Asthma vs. Control Subjects) | P Value‡ (Severe vs. Nonsevere) |
---|---|---|---|---|---|---|
Age at enrollment, yr | 33 ± 13 | 37 ± 13 | 33 ± 12 | 44 ± 11 | 0.19 | <0.0001 |
Sex, n (%) female | 15 (56) | 86 (67) | 51 (65) | 35 (70) | 0.27 | 0.7 |
Race (% White/African American/other§) | 70/19/11 | 60/31/9 | 56/32/11 | 65/29/6 | 0.43 | 0.55 |
Body mass index, kg/m2 | 26 ± 5.2 | 30 ± 6.9 | 29 ± 6.7 | 32 ± 7.0 | 0.0016 | 0.029 |
Baseline Pre-BD FEV1% predictedǁ | 94 ± 9.1 | 72 ± 22.1 | 82 ± 17 | 56 ± 20 | <0.0001 | <0.0001 |
Baseline Pre-BD FEV1/FVCǁ | 0.81 ± 0.04 | 0.70 ± 0.12 | 0.75 ± 0.09 | 0.61 ± 0.12 | <0.0001 | <0.0001 |
SARP Longitudinal Cohort RNAseq (n = 156) | Nonsmoking Control Subjects (n = 42) | Nonsmoking Asthma* (n = 114) | Nonsevere Asthma† (n = 52) | Severe Asthma† (n = 62) | P value‡ (Asthma vs. Control Subjects) | P value‡ (Severe vs. Nonsevere) |
---|---|---|---|---|---|---|
Age at enrollment, yr | 41 ± 13 | 41 ± 13 | 37 ± 12 | 44 ± 13 | 0.92 | 0.0032 |
Sex, n (%) female | 25 (60) | 74 (65) | 34 (65) | 40 (65) | 0.58 | 1 |
Race (% White/African American/other§) | 69/17/14 | 63/25/12 | 67/21/12 | 60/27/13 | 0.57 | 0.69 |
Body mass index, kg/m2 | 28 ± 5.5 | 31 ± 8.7 | 30 ± 9.1 | 32 ± 8.3 | 0.033 | 0.025 |
Baseline Pre-BD FEV1% predictedǁ | 99 ± 12 | 76 ± 19 | 85 ± 15 | 69 ± 20 | <0.0001 | <0.0001 |
Baseline Pre-BD FEV1/FVCǁ | 0.81 ± 0.04 | 0.70 ± 0.08 | 0.73 ± 0.09 | 0.68 ± 0.10 | <0.0001 | 0.015 |
Definition of abbreviations: Pre-BD = prebronchodilator; SARP = Severe Asthma Research Program.
For the longitudinal cohort, nonsmokers were never-smokers or previous smokers with less than 5 to 10 pack-years of tobacco use, depending on age. For the cross-sectional cohort, nonsmokers were never-smokers or previous smokers with less than 5 pack-years of tobacco use.
Asthma severity (nonsevere or severe asthma) was on the basis of American Thoracic Society–European Respiratory Society criteria (29).
P value was generated using the Kruskal-Wallis test.
Other races include Hispanic, Asian, American Indian, and mixed.
Pre-BD pulmonary function was presented.